AstraZeneca PLC fourth quarter and full year results 2013
6 February 2014 | By AstraZeneca
"As expected, our financial performance for 2013 reflects the ongoing impact from the loss of exclusivity for several key brands..."
List view / Grid view
6 February 2014 | By AstraZeneca
"As expected, our financial performance for 2013 reflects the ongoing impact from the loss of exclusivity for several key brands..."
3 February 2014 | By AstraZeneca
AstraZeneca announced that it completed, on 1 February 2014, the acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance...
14 January 2014 | By AstraZeneca
At the conference, Pascal Soriot will provide an update on the company’s development pipeline and outline its strategic priorities for 2014...
19 December 2013 | By AstraZeneca
Global agreement strengthens AstraZeneca’s commitment to diabetes, a key growth platform in a core strategic area for the company...
6 August 2013 | By Financial Times
3 – 4 December 2013, The InterContinental Park Lane, London...
31 July 2013 | By AstraZeneca
Collaboration to include US, China and selected other markets...
15 July 2013 | By AstraZeneca
AstraZeneca announced that Simon Lowth, CFO and Executive Director, will leave the company at the end of October...
18 June 2013 | By AstraZeneca
"AstraZeneca’s investment is excellent news for the UK life sciences industry..."
10 June 2013 | By AstraZeneca
AstraZeneca has entered into a definitive agreement to acquire Pearl Therapeutics...
28 May 2013 | By AstraZeneca
AstraZeneca announced that it has entered into a definitive agreement to acquire Omthera Pharmaceuticals...
21 March 2013 | By AstraZeneca
AstraZeneca announced that Marc Dunoyer is to join the company...
21 March 2013 | By AstraZeneca
Agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer...
21 March 2013 | By AstraZeneca
AstraZeneca will outline its strategy to return to growth and achieve scientific leadership...
18 March 2013 | By AstraZeneca
Centres positioned to take better advantage of bioscience clusters...
15 January 2013 | By AstraZeneca
AstraZeneca unveiled changes to its executive leadership team...